Type 2 diabetes is associated with oxidative stress and abnormal lipid metabolism due to hyperglycaemia and hyperlipidaemia. Increased reactive oxygen species (ROS) generation and lipid peroxidation activate stress-sensitive intracellular signalling pathways such as the transcription of NF-κB, which plays a central role in inflammation-related disease(Reference Hotamisligil1). In addition, hyperglycaemia accelerates the formation of advanced glycation endproducts (AGE), which are proteins produced from non-enzymic glycation reactions(Reference Ahmed2). AGE and their binding with receptors, such as the receptor for AGE (RAGE), galectin-3 and CD36, induce free radical formation. They accumulate during the normal ageing process and at accelerated rates during the course of diabetes, and are associated with the pathogenesis of chronic diseases such as arthritis, atherosclerosis, liver cirrhosis and diabetic nephropathy(Reference Goh and Cooper3). Therefore, the attenuation of oxidative stress during the initiation and propagation of type 2 diabetes is important to prevent a vicious cycle of inflammatory responses and tissue damage. Moreover, insulin resistance in type 2 diabetes leads to a marked disruption of lipid dynamics, often reflected by elevated levels of circulating NEFA and TAG, together with excess fat deposition in various tissues(Reference Delarue and Magnan4). Lipid homeostasis is regulated by a transcription factor, sterol regulatory element-binding protein (SREBP), which is highly expressed in the presence of metabolic disorders such as obesity and diabetes. In particular, up-regulated SREBP-1 has been suggested to play a central role in the development of hepatic steatosis in an insulin-resistant animal model(Reference Browning and Horton5). Accordingly, to prevent diabetic hepatic damage induced by inflammation and/or excess lipid accumulation, it is important to reduce oxidative stress and inhibit lipid synthesis in the liver.
Currently, functional food and/or dietary ingredients with health benefits are being given much attention due to the absence of adverse effects, abundant production and application to various commercial goods(Reference Jones and Varady6). Oligonol is a phenolic product derived from lychee fruit extract containing catechin-type monomers and oligomers of proanthocyanidins, produced by a manufacturing process which converts polyphenol polymers into oligomers(Reference Tanaka, Yoshitake and Zhao7, Reference Fujii, Nishioka and Wakame8). Oligonol is produced by the oligomerisation of polyphenol polymers, typically proanthocyanidins; thus, oligonol delivers higher levels of oligomeric proanthocyanidins compared with fruit and plant sources that generally contain high-molecular-weight proanthocyanidins. There is accumulating evidence that oligonol can exert some biological effects in vitro and in vivo: anticancer(Reference Jo, Lee and Ahn9), as well as antioxidant and anti-inflammatory effects(Reference Kundu, Chang and Fujii10), beneficial activity for NO bioavailability(Reference Zhang, Yokoo and Nishioka11) and a regulatory effect on lipid metabolism(Reference Sakurai, Nishioka and Fujii12, Reference Ogasawara, Kitadate and Nishioka13). Indeed, dietary feeding with proanthocyanidins, which comprise oligonol, has been reported to induce a significant attenuation of tissue fat levels, without changing the total body mass of the animals compared with non-proanthocyanidin-fed animals(Reference Mittal, Elmets and Katiyar14). However, there is no evidence to support whether or not oligonol has any effect on oxidative stress-induced inflammation and abnormal lipid accumulation in the liver of obesity-induced type 2 diabetes. Therefore, we investigated the effects of oligonol on hepatic damage induced by hyperglycaemia, abnormal lipid synthesis and NF-κB-related inflammation, using a typical type 2 diabetic animal, the C57BLKS/J db/db mouse.
Materials and methods
Oligonol
Oligonol was generated by oligomerising polyphenol polymers derived from lychee fruit. The safety of oligonol as a food or dietary supplement and as a pharmaceutical additive has already been confirmed, as described previously(Reference Fujii, Nishioka and Wakame8). Oligonol comprises a polyphenol mixture of 16·0 % monomers (catechin, epicatechin, epicatechin gallate and epigallocatechin gallate) and 13·9 % dimers (procyanidin A1, A2, B1 and B2), while lychee fruit polyphenols comprise a mixture of 6·4 % monomers and 9·8 % dimers. Oligonol is commercially available (Amino Up Chemical Co., Ltd, Sapporo, Japan).
Materials
Protease inhibitor mixture solution, 4,6-dihydroxy-2-mercaptopyrimidine (2-thiobarbituric acid), EDTA, reduced glutathione (GSH) and oxidised glutathione (GSSG) were purchased from Wako Pure Chemical Industries, Ltd (Osaka, Japan). 2′,7′-Dichlorofluorescein diacetate was purchased from Molecular Probes (Eugene, OR, USA). The Bio-Rad protein assay kit and pure nitrocellulose membrane were purchased from Bio-Rad Laboratories (Tokyo, Japan). β-Actin, o-phthalaldehyde, phenylmethylsulfonyl fluoride and N-ethylmaleimide were purchased from Sigma Chemical Co. (St Louis, MO, USA). Rabbit polyclonal antibodies against PPARα, SREBP-1, SREBP-2, NF-κBp65 and RAGE, and mouse monoclonal antibody against cyclo-oxygenase-2 (COX-2) and inducible NO synthase (iNOS) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Monoclonal anti-N ɛ-(carboxyethyl)lysine (CEL) antibody and polyclonal anti-N ɛ-(carboxymethyl)lysine (CML) antibody were kindly provided by Dr R. Nagai (Kumamoto University, Kumamoto, Japan). Goat anti-rabbit and goat anti-mouse IgG horseradish peroxidase-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology, Inc. ECLTM Western Blotting Detection Reagents were purchased from Amersham Bioscience (Piscataway, NJ, USA).
Experimental protocol
The ‘Guidelines for Animal Experimentation’ approved by the University of Toyama were followed in the present study (registration no. S-2006 INM-22). Male C57BLKS/J db/db and age-matched m/m mice, aged 5 weeks, were purchased from Japan SLC Inc. (Hamamatsu, Japan). C57BLKS/J m/m mice were used as a normal control in the experiment. Mice were maintained under a 12 h light–dark cycle, fed a standard laboratory pellet chow (comprising 24·0 % protein, 3·5 % lipids and 60·5 % carbohydrate; CLEA Japan Inc., Tokyo, Japan) and water ad libitum, and housed in a room with a controlled temperature (23 ± 3°C) and humidity (about 60 %). Oligonol (10 or 20 mg/kg body weight per d) was orally administered to db/db mice (Oligo-10 or Oligo-20, n 10, respectively), while vehicle-treated db/db (n 10) and non-diabetic control m/m (n 6) mice received water every day for 8 weeks. The body weight, food intake and water intake were measured every day during the treatment period. After 8 weeks of oligonol treatment, blood samples were collected from anaesthetised mice by cardiac puncture. The serum was immediately separated from blood samples by centrifugation. Subsequently, to remove the remaining blood in the liver, each mouse was perfused with ice-cold physiological saline by syringe after cardiac puncture, and the liver was harvested, plunged into liquid N2 and stored at − 80°C until analysis.
Measurement of serum parameters
Serum glucose, TAG, total cholesterol and NEFA levels were measured using a commercial kit (Glucose CII-Test, Triglyceride E-Test, Cholesterol E-Test and NEFA C-Test from Wako Pure Chemical Industries, Ltd, Osaka, Japan). The serum ROS level was determined using the method of Ali et al. (Reference Ali, LeBel and Bondy15) and the thiobarbituric acid-reactive substance (TBARS) concentration was examined employing the method of Naito & Yamanaka(Reference Naito and Yamanaka16). Hepatic functional parameters (alanine aminotransferase and aspartate aminotransferase) were measured using a Wako kit (Transaminase CII-Test).
Measurement of hepatic TAG and total cholesterol contents
Hepatic tissues were homogenised in ice-cold 0·9 % NaCl buffer. Then the homogenate was extracted with a mixture of chloroform and methanol (2:1, v/v) according to the method of Folch et al. (Reference Folch, Lees and Sloane Stanley17), and the mixture was centrifuged at 1670 g for 15 min. The organic layer was collected and dried, and the residue was dissolved in isopropanol. Determinations for TAG and total cholesterol contents were performed using the Wako kit.
Assessment of hepatic reactive oxygen species generation and thiobarbituric acid-reactive substance levels
ROS generation was measured using the method of Ali et al. (Reference Ali, LeBel and Bondy15). Hepatic tissues were homogenised on ice with 1 mm-EDTA–50 mm-sodium phosphate buffer (pH 7·4), and then 25 mm-2′,7′-dichlorofluorescein diacetate was added to homogenates. After incubation for 30 min, the changes in fluorescence values were determined at an excitation wavelength of 486 nm and emission wavelength of 530 nm. The hepatic TBARS content, an oxidative stress biomarker, was determined employing the method of Mihara & Uchiyama(Reference Mihara and Uchiyama18).
Determination of hepatic reduced glutathione and oxidised glutathione levels
GSH and GSSG assays were carried out applying the method of Hissin & Hilf(Reference Hissin and Hilf19). Hepatic tissues were homogenised on ice with 1 mm-EDTA–50 mm-sodium phosphate buffer (pH 7·4). Then, 25 % metaphosphoric acid was added for protein precipitation. The homogenate was centrifuged at 4°C at 100 000 g for 30 min to obtain the supernatant fraction for the assays of GSH and GSSG. To assay GSH, 1 mm-EDTA–50 mm-sodium phosphate buffer (pH 7·4) was added to the supernatant fraction, followed by the addition of o-phthalaldehyde. After 20 min at room temperature, fluorescence was estimated at an excitation wavelength of 360 nm and emission wavelength of 460 nm. GSSG was assayed after pre-incubation with N-ethylmaleimide for 20 min, and 0·1 m-NaOH was substituted for the phosphate buffer. After incubation for 20 min at room temperature, the fluorescence value was estimated at an excitation wavelength of 360 nm and emission wavelength of 460 nm. Protein assays were carried out according to the method of Itzhaki & Gill(Reference Itzhaki and Gill20) using bovine serum albumin as a standard.
Preparation of nuclear and post-nuclear fractions
To prepare nuclear fractions, hepatic tissues were homogenised with ice-cold lysis buffer containing 5 mm-2-amino-2-hydroxymethyl-propane-1,3-diol (Tris)-HCl (pH 7·5), 2 mm-MgCl2, 15 mm-CaCl2 and 1·5 m-sucrose, and then 0·1 m-dithiothreitol (DTT) and protease inhibitor cocktail were added. After centrifugation (10 500 g for 20 min at 4°C), the pellet was suspended with extraction buffer containing 20 mm-2-[4-(2-hydroxyethyl)-1-piperazyl] ethanesulfonic acid (pH 7·9), 1·5 mm-MgCl2, 0·42 m-NaCl, 0·2 mm-EDTA and 25 % (v/v) glycerol, and then 0·1 m-DTT and protease inhibitor cocktail were added. The mixture was placed on ice for 30 min. The nuclear fraction was prepared by centrifugation at 20 500 g for 5 min at 4°C. The post-nuclear fraction was extracted from the liver of each mouse, as described below. In brief, hepatic tissue was homogenised with ice-cold lysis buffer (pH 7·4) containing 137 mm-NaCl, 20 mm-Tris-HCl, 1 % Tween 20, 10 % glycerol, 1 mm-phenylmethylsulfonyl fluoride and protease inhibitor mixture solution. The homogenate was then centrifuged at 2000 g for 10 min at 4°C. The protein concentration of each fraction was determined using a commercial kit (Bio-Rad Laboratories, Hercules, CA, USA).
Western blot analyses
For the determination of NF-κB, PPARα, SREBP-1 and SREBP-2, 30 μg protein of each nuclear fraction was electrophoresed through 8 % SDS-PAGE. Separated proteins were transferred to a nitrocellulose membrane, blocked with 5 % (w/v) skimmed milk solution for 1 h, and then incubated with primary antibodies to NF-κBp65, PPARα, SREBP-1, SREBP-2 and β-actin, respectively, overnight at 4°C. After the blots were washed, they were incubated with anti-rabbit or anti-mouse IgG horseradish peroxidase-conjugated secondary antibody for 1·5 h at room temperature. Also, 30 μg of protein of each post-nuclear fraction for COX-2, iNOS, RAGE, CEL and CML were electrophoresed through 8 % SDS-PAGE. Each antigen–antibody complex was visualised using ECL Western Blotting Detection Reagents and detected by chemiluminescence with LAS-4000 (Fujifilm, Tokyo, Japan). Band densities were determined using ATTO Densitograph Software (ATTO Corporation, Tokyo, Japan) and quantified as the ratio to β-actin. These protein levels of groups are expressed relative to those of m/m mice (represented as 1).
Quantitative real-time PCR
Total RNA was isolated from hepatic tissue using Trizol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) and quantified with NanoDrop (Thermo Scientific, Wilmington, DE, USA). The cDNA were synthesised from 5 μg of RNA using RT (QIAGEN, Tokyo, Japan). For the real-time PCR, triplicate samples of serially diluted cDNA samples were used in a reaction mixture that contained 1 μm of each primer in a reaction volume of 50 μl using the SYBR Green Real-time PCR kit (QIAGEN, Tokyo, Japan) and a fluorometric thermal cycler (Mx3000PTM; Stratagene, La Jolla, CA, USA). Reaction mixtures were incubated for an initial denaturation at 95°C for 15 min, followed by forty-five cycles at 94°C for 15 s, 60°C for 30 s and 72°C for 30 s. Primers used were as follows: acetyl-CoA carboxylase (ACC; sense: CCCAGCAGAATAAAGCTACTTTGG, antisense: TCCTTTTGTGCAACTAGGAACGT), fatty acid synthase (FAS; sense: CCTGGATAGCATTCCGAACCT, antisense: AGCACATCTCGAAGGCTACACA) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR; sense: AGCCGAAGCAGCACATGAT, antisense: CTTGTGGAATGCCTTGTGATTG). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was employed as an endogenous control. The ΔCT method was used for relative quantification. The ΔCT value for each sample was determined by calculating the difference between the CT value of the target gene and that of the GAPDH reference gene. The normalised target gene expression level in the sample was calculated using the formula 2− ΔΔCT as the fold change over the control.
Histology
The excised parts of livers were immediately fixed with 10 % neutral-buffered formalin and, after embedding in paraffin, they were cut into 5 μm-thick sections. After oil red O staining, these sections were examined with a light microscope.
Statistical analysis
Data are expressed as mean values with their standard errors. Statistical comparisons were performed by one-way ANOVA followed by Duncan's multiple-range test. Statistical analysis was conducted using SAS (release 9.2; SAS Institute, Inc., Cary, NC, USA) and P < 0·05 was considered significant.
Results
General characteristics
Type 2 diabetic characteristics such as excessive body-weight gain, food intake and water intake were exhibited in db/db mice at age 17 weeks compared with normal m/m mice (Table 1). The liver weight was higher in db/db than m/m mice; however, oligonol administrations led to no significant differences in db/db groups. In serum analyses, glucose and lipid concentrations were increased in db/db compared with m/m mice; however, except for serum glucose, oligonol administration significantly reduced serum concentrations of TAG, total cholesterol and NEFA at 20 mg/kg doses (Table 1). In addition, oxidative stress-related parameters, ROS and TBARS, were enhanced in vehicle db/db compared with m/m mice. However, oligonol treatment at 20 mg/kg significantly reduced the ROS level and inhibited lipid peroxidation in the serum of db/db mice (Table 1). Regarding hepatic functional parameters, serum alanine aminotransferase and aspartate aminotransferase levels in vehicle db/db mice were elevated compared with m/m mice, while, in oligonol-administered db/db mice, only the alanine aminotransferase level was significantly decreased (Table 1).
Table 1 General characteristics and serum analyses after 8 weeks' treatment with oligonol
(Mean values with their standard errors)
db/db, Diabetic; m/m, Misty; Veh, db/db vehicle-treated mice; Oligo-10, db/db mice treated with oligonol at 10 mg/kg body weight; Oligo-20, db/db mice treated with oligonol at 20 mg/kg body weight; ROS, reactive oxygen species; TBARS, thiobarbituric acid-reactive substances; MDA, malondialdehyde; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
a,b,c Mean values within a row with unlike superscript letters were significantly different (P < 0·05; Duncan's test).
Hepatic biomarkers associated with oxidative stress
As shown in Fig. 1, the hepatic levels of ROS and TBARS in vehicle-treated db/db mice were apparently higher than those of m/m mice, whereas these enhanced levels were significantly reduced by oligonol treatment in a dose-dependent manner. Concerning the hepatic GSH, GSSG and GSH:GSSG ratio, there were significant alterations between vehicle db/db and m/m groups. Oligonol administration significantly augmented the GSH:GSSG ratio due to a marked decrease in the GSSG level in the liver of db/db mice.
Fig. 1 Biomarkers associated with oxidative stress in the liver: (A) reactive oxygen species (ROS); (B) thiobarbituric acid-reactive substances (TBARS); (C) reduced glutathione (GSH); (D) oxidised glutathione (GSSG); (E) GSH:GSSG ratio. m/m, Misty; db/db, diabetic; Veh, db/db vehicle-treated mice; Oligo-10, db/db mice treated with oligonol at 10 mg/kg body weight; Oligo-20, db/db mice treated with oligonol at 20 mg/kg body weight; MDA, malondialdehyde. Values are means (n 6 or n 10), with standard errors represented by vertical bars. a,b,c Mean values with unlike letters were significantly different (P < 0·05; Duncan's test).
Hepatic NF-κBp65, cyclo-oxygenase-2 and inducible NO synthase expressions
At the end of the experiment, hepatic NF-κBp65- and NF-κB-mediated target protein expression levels in the vehicle-treated db/db group were significantly up-regulated compared with those in the m/m group (Fig. 2). The administration of oligonol suppressed the transcription of NF-κB in the liver. Also, up-regulated hepatic iNOS expression levels were reduced on oligonol treatment at 20 mg/kg. Concerning hepatic COX-2 protein expression, oligonol treatment showed a reducing tendency, but this was not significant.
Fig. 2 NF-κBp65 (A), cyclo-oxygenase-2 (COX-2) (B) and inducible NO synthase (iNOS) (C) expressions in the liver. m/m, Misty; db/db, diabetic; Veh, db/db vehicle-treated mice; Oligo-10, db/db mice treated with oligonol at 10 mg/kg body weight; Oligo-20, db/db mice treated with oligonol at 20 mg/kg body weight. Values are means (n 6 or n 10), with standard errors represented by vertical bars. a,b Mean values with unlike letters were significantly different (P < 0·05; Duncan's test).
Hepatic receptor for advanced glycation endproducts, Nɛ-(carboxyethyl)lysine and Nɛ-(carboxymethyl)lysine expressions
In Fig. 3, protein expressions of AGE-related proteins were enhanced in the db/db mouse liver at 17 weeks. The db/db mice showed up-regulated protein expressions of RAGE and CML, but the oral administration of oligonol attenuated these protein levels. Hepatic CEL protein expression remained unchanged in all experimental groups.
Fig. 3 Receptor for advanced glycation endproduct (RAGE) (A), N ɛ-(carboxyethyl)lysine (CEL) (B) and N ɛ-(carboxymethyl)lysine (CML) (C) expressions in the liver. m/m, Misty; db/db, diabetic; Veh, db/db vehicle-treated mice; Oligo-10, db/db mice treated with oligonol at 10 mg/kg body weight; Oligo-20, db/db mice treated with oligonol at 20 mg/kg body weight. Values are means (n 6 or n 10), with standard errors represented by vertical bars. a,b Mean values with unlike letters were significantly different (P < 0·05; Duncan's test).
Hepatic TAG and total cholesterol contents
The hepatic contents of TAG and total cholesterol in vehicle-treated db/db mice were significantly elevated compared with m/m mice (Fig. 4). In the oligonol-treated group, hepatic TAG and total cholesterol contents were markedly decreased on oligonol administration.
Fig. 4 Hepatic TAG (A) and total cholesterol (B) contents. m/m, Misty; db/db, diabetic; Veh, db/db vehicle-treated mice; Oligo-10, db/db mice treated with oligonol at 10 mg/kg body weight; Oligo-20, db/db mice treated with oligonol at 20 mg/kg body weight. Values are means (n 6 or n 10), with standard errors represented by vertical bars. a,b Mean values with unlike letters were significantly different (P < 0·05; Duncan's test).
Hepatic lipogenic enzyme mRNA expressions
To examine the effects of oligonol administration on the hepatic mRNA levels of genes involved in fatty acid and cholesterol synthesis, quantitative real-time PCR was performed (Fig. 5). mRNA expressions of lipogenic enzymes for TAG synthesis (ACC and FAS) and cholesterol synthesis (HMGR) were over-expressed in the hepatic tissue of vehicle db/db mice compared with the m/m group. However, oligonol-treated db/db mice exhibited significantly lower expressions of ACC, FAS and HMGR than db/db vehicle mice.
Fig. 5 Hepatic mRNA expressions of acetyl-CoA carboxylase (ACC) (A), fatty acid synthase (FAS) (B) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) (C). m/m, Misty; db/db, diabetic; Veh, db/db vehicle-treated mice; Oligo-10, db/db mice treated with oligonol at 10 mg/kg body weight; Oligo-20, db/db mice treated with oligonol at 20 mg/kg body weight. Values are means (n 6 or n 10), with standard errors represented by vertical bars. a,b Mean values with unlike letters were significantly different (P < 0·05; Duncan's test).
Hepatic PPARα, sterol regulatory element-binding protein-1 and sterol regulatory element-binding protein-2 expressions
As shown in Fig. 6, hepatic expressions of transcriptional factors related to lipid regulation, PPARα, SREBP-1 and SREBP-2, were examined by Western blotting. There was no alteration in PPARα and SREBP-2 expressions in the livers of all experimental groups of mice. SREBP-1 protein expression was higher in vehicle db/db than m/m mice, but, in the group treated with oligonol at 20 mg/kg, hepatic SREBP-1 expression was significantly decreased (Fig. 6).
Fig. 6 PPARα (A), sterol regulatory element-binding protein (SREBP)-1 (B) and SREBP-2 (C) expressions in the liver. m/m, Misty; db/db, diabetic; Veh, db/db vehicle-treated mice; Oligo-10, db/db mice treated with oligonol at 10 mg/kg body weight; Oligo-20, db/db mice treated with oligonol at 20 mg/kg body weight. Values are means (n 6 or n 10), with standard errors represented by vertical bars. a,b Mean values with unlike letters were significantly different (P < 0·05; Duncan's test).
Histological examinations
Fig. 7 shows the results of histological examinations using oil red O staining, which detects fat deposits. The level of lipid deposition was higher in the liver of db/db control mice compared with that of m/m mice. However, oligonol-treated db/db mice clearly showed decreased fat accumulation.
Fig. 7 Oil red O staining of the liver. Upper panel (A, C, E, G), × 20; lower panel (B, D, F, H), × 40. (A and B) Misty (m/m) mice; (C and D) diabetic (db/db) vehicle-treated mice; (E and F) db/db mice treated with oligonol at 10 mg/kg body weight; (G and H) db/db mice treated with oligonol at 20 mg/kg body weight.
Discussion
Hyperglycaemia and elevated NEFA levels result in the generation of ROS, and, consequently increase oxidative stress(Reference Brownlee21). ROS are believed to play a direct, key role in the pathogenesis of diabetic complications, because of their ability to directly oxidise and damage DNA, protein and lipids, consequently resulting in cell dysfunction and apoptosis(Reference Rösen, Nawroth and King22, Reference Newsholme, Haber and Hirabara23). In the present results, the experimental type 2 diabetes model mice exhibited higher oxidative stress levels caused by increased ROS and lipid peroxidation, along with a lower hepatic GSH:GSSG ratio, compared with normal m/m mice. Conversely, oligonol treatment significantly reduced ROS and TBARS levels in both the serum and liver of db/db mice. In addition, the reduced GSH:GSSG ratio of vehicle db/db mice was increased by oligonol administration due to a reduction of the GSSG concentration in the liver. Actually, oligonol comprises catechin-type monomers and oligomers, which have well-recognised antioxidant and radical-scavenging effects in vitro and in vivo (Reference Higdon and Frei24, Reference Perron and Brumaghim25). Consequently, these results demonstrate that oligonol effectively attenuated oxidative stress, at least in part, through the direct inhibition of ROS and lipid peroxidation rather than the improvement of hyperglycaemia.
In type 2 diabetes, the redox-sensitive intracellular signalling pathway is altered. In particular, one major intracellular target of hyperglycaemia and oxidative stress is the transcription factor NF-κB. NF-κB can be activated by a wide array of exogenous and endogenous stimuli including hyperglycaemia, elevated NEFA, ROS, TNF-α, IL-1β, other pro-inflammatory cytokines, AGE-binding RAGE and p38 mitogen-activated protein kinase. The activation of NF-κB induces the inflammation-related proteins COX-2 and iNOS, and subsequent production of PG and NO, respectively. NO reacts very rapidly with superoxide to form peroxynitrite and other NO-derived oxidants capable of damaging DNA and proteins(Reference Surh, Chun and Cha26). There is a vicious cycle involving NF-κB, oxidative stress and inflammation under the diabetic condition. Therefore, the inhibition of NF-κB transcription plays a central role in regulating the pathophysiology of diabetic complications. In the present study, elevated protein expressions of NF-κBp65 and iNOS in the liver of db/db mice were markedly down-regulated by oligonol administration. Oligonol administration could adjust inflammation through the inhibition of the NF-κB pathway.
Hyperglycaemia in diabetes accelerates the synthesis and tissue deposition of AGE, an abnormality contributing to the pathogenesis of morbid complications. The progression of AGE generation was also stimulated by enhanced oxidative stress because ROS induce the auto-oxidation of Amadori products, and a decrease in GSH levels impairs the activity of glyoxalase, the major AGE-detoxifying enzyme(Reference Vander Jagt, Hassebrook and Hunsaker27). Two distinctive AGE, CEL and CML, are formed on proteins by glycoxidation and/or lipid peroxidation pathways. AGE-modified molecules interact with specific cell-surface receptors (RAGE), activating several intracellular signal transduction pathways such as the induction of NF-κB transcription and mitogen-activated protein kinase followed by the further stimulation of oxidative stress and inflammatory responses(Reference Yeh, Sturgis and Haidacher28). Moreover, up-regulated RAGE expression is related to hepatic fibrogenesis through a parallel increase in transforming growth factor-β1 and procollagen, which play central roles in fibrosis progression(Reference Lohwasser, Neureiter and Popov29). The present study showed that oligonol was effective at attenuating oxidative stress and inhibiting NF-κB transcription. Therefore, oligonol was assumed to down-regulate AGE-related protein expression in the liver. In Western blot analysis, hepatic RAGE, CEL and CML expressions in db/db mice were elevated, compared with those in m/m mice. However, oligonol administration significantly attenuated RAGE and CML expressions in the liver of db/db mice. Oligonol treatment more effectively attenuated hepatic CML compared with CEL, at least in part, because CML formation is linked with lipid peroxidation and peroxynitrite production induced by iNOS activity(Reference Nagai, Unno and Hayashi30).
Diabetes is characterised by hyperglycaemia together with biochemical alterations of glucose and lipid metabolism, which is due to impaired carbohydrate utilisation resulting from deficient insulin secretion and/or insulin resistance. In particular, insulin resistance elevates the hepatic output of TAG-rich particles and adipose release of NEFA. When the NEFA supply exceeds utilisation, non-adipose tissues start accumulating TAG, which is aggravated by the simultaneous presence of hyperglycaemia. In the present study, db/db mice represented obesity-induced diabetes, along with hyperglycaemia and hyperlipidaemia. The administration of oligonol for 8 weeks to db/db mouse groups led to a significant decrease in the serum lipid profile, such as TAG, total cholesterol and NEFA levels, without changes in serum glucose (Table 1). These results indicate that oligonol can ameliorate diabetic pathological conditions related to abnormal lipid metabolism in type 2 diabetes.
Hyperglycaemia and abnormalities in serum lipids can contribute to diverse lipid metabolic changes occurring in the liver, which are strongly associated with the progression of diabetic liver disease. Obesity-induced insulin resistance, which is a typical characteristic of type 2 diabetes, leads to reduced hepatic fatty acid oxidation and increased de novo lipogenesis, and, consequently, excess fat accumulation in the liver(Reference Kahn, Hull and Utzschneider31). Consistent with the results for serum lipids, the oligonol-administered group showed a significant reduction in hepatic TAG and total cholesterol contents compared with the vehicle group (Fig. 4). Next, we analysed the effect of oligonol on hepatic mRNA levels of lipid-synthesising enzymes such as ACC, FAS and HMGR. ACC is an important rate-controlling enzyme involved in the synthesis of malonyl-CoA, which is both a critical precursor for the biosynthesis of fatty acids and a potent inhibitor of mitochondrial fatty acid oxidation. The phosphorylation and inhibition of ACC by AMP-activated protein kinase led to a fall in the malonyl-CoA content and a subsequent decrease in TAG synthesis, concomitant with an increase in β-oxidation(Reference Velasco, Geelen and Guzmán32). In the present study, oligonol markedly lowered the mRNA expression of hepatic ACC and FAS, a key enzyme that catalyses the synthesis of saturated long-chain fatty acids, compared with control db/db mice. Also, mRNA expression of HMGR, a key enzyme in cholesterol synthesis, was significantly down-regulated by oligonol treatment. It was confirmed that oligonol inhibited hepatic lipid synthesis and accumulation via the suppression of lipogenic enzyme activity.
Lipid metabolism is regulated by several nuclear transcription factors such as SREBP. In the present study, hepatic SREBP-1 in db/db mice was significantly down-regulated by the administration of oligonol. However, oligonol administration led to no significant alteration of PPARα and SREBP-2. These findings were related to the inhibition of hepatic TAG and cholesterol accumulation. HMGR is the main target gene regulated by SREBP-2 and also by SREBP-1, and, therefore, up-regulated SREBP-1 is related to cholesterol synthesis(Reference Bennett, Seo and Datta33, Reference Kaplan, Kerry and Aviram34). This may explain why the reduced hepatic cholesterol content caused by oligonol treatment was mediated by the down-regulation of SREBP-1 without any change in SREBP-2 expression.
In summary, the present results show that oligonol ameliorated oxidative stress and dyslipidaemia in a type 2 diabetic db/db mouse model. Oligonol administration inhibited oxidative stress and inflammation through the reduction of ROS generation, lipid peroxidation, and, in turn, the down-regulation of NF-κB and iNOS protein. Furthermore, the 8-week administration of oligonol prevented dyslipidaemia compared with the vehicle group, which, in turn, reduced the expression of SREBP-1 protein and its target genes ACC, FAS and HMGR, leading to the low-level hepatic lipid deposition of TAG and cholesterol. Consistent with another report(Reference Lee, Cho and Yokozawa35), the body weight, food intake and water intake of db/db mice in our present study were markedly higher than those of m/m mice due to augmented food consumption in the former. However, the administration of oligonol for 8 weeks led to no difference in these items. There was no hypoglycaemic effect of oligonol administration in db/db mice. Accordingly, the present study suggests that the anti-diabetic effects of oligonol are associated with ameliorations of oxidative stress and abnormal lipid metabolism in type 2 diabetes.
Acknowledgements
The present study was supported in part by a grant-in-aid (C) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (no. 19500661 to T. Y.).
T. Y. designed the experiment and wrote the manuscript. All the authors read, commented on and approved the submitted version.
The authors declare that there are no conflicts of interest.
